Insider · CIK 0001553338

Waddill William D.

Reports to the SEC for 6 companies · NEWARK, CA

sec.gov

Transactions

Companies

Filings

CIK

0001553338

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-23	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Director	MExercise/Conversion	+9,000 sh	$16.54	+$149K	16,825
2026-06-23	PTGXProtagonist Therapeutics, IncS Sale	Director	SSale	−9,000 sh	$117.94	−$1.06M	7,825
2026-06-23	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−9,000 sh	—	—	0
2026-06-11	ANNXAnnexon, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+65K sh	—	—	65,000
2026-06-10	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Director	MExercise/Conversion	+3,000 sh	$11.80	+$35.4K	10,825
2026-06-10	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Director	MExercise/Conversion	+6,000 sh	$16.54	+$99.2K	16,825
2026-06-10	PTGXProtagonist Therapeutics, IncS Sale	Director	SSale	−9,000 sh	$107.68	−$969K	7,825
2026-06-10	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−3,000 sh	—	—	0
2026-06-10	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−6,000 sh	—	—	9,000
2026-05-29	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Director	MExercise/Conversion	+9,000 sh	$11.80	+$106K	16,825
2026-05-29	PTGXProtagonist Therapeutics, IncS Sale	Director	SSale	−9,000 sh	$99.64	−$897K	7,825
2026-05-29	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−9,000 sh	—	—	3,000
2026-02-06	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Director	MExercise/Conversion	+20K sh	$8.31	+$166K	27,825
2026-02-06	PTGXProtagonist Therapeutics, IncS Sale	Director	SSale	−20K sh	$83.68	−$1.67M	7,825
2026-02-06	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−20K sh	—	—	0
2026-01-02	PTGXProtagonist Therapeutics, IncA Award	Director	AAward	+2,695 sh	—	—	7,825
2026-01-02	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)A Award	Director	AAward	+3,762 sh	—	—	3,762
2025-12-19	ARWRARROWHEAD PHARMACEUTICALS, INC.S Sale	Director	SSale	−2,416 sh	$66.66	−$161K	62,514
2025-12-19	ARWRARROWHEAD PHARMACEUTICALS, INC.S Sale	Director	SSale	−5,451 sh	$68.01	−$371K	57,063
2025-12-19	ARWRARROWHEAD PHARMACEUTICALS, INC.S Sale	Director	SSale	−500 sh	$68.53	−$34.3K	56,563
2025-12-16	ARWRARROWHEAD PHARMACEUTICALS, INC.A Award	Director	AAward	+7,819 sh	—	—	64,930
2025-10-10	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Director	MExercise/Conversion	+12K sh	$6.98	+$83.8K	17,130
2025-10-10	PTGXProtagonist Therapeutics, IncS Sale	Director	SSale	−4,000 sh	$69.25	−$277K	13,130
2025-10-10	PTGXProtagonist Therapeutics, IncS Sale	Director	SSale	−8,000 sh	$87.81	−$702K	5,130
2025-10-10	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−12K sh	—	—	0
2025-09-22	PTGXProtagonist Therapeutics, IncS Sale	Director	SSale	−4,000 sh	$64.25	−$257K	5,130
2025-08-27	PTGXProtagonist Therapeutics, IncS Sale	Director	SSale	−4,000 sh	$59.25	−$237K	9,130
2025-06-05	ANNXAnnexon, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+55K sh	—	—	55,000
2025-03-17	PTGXProtagonist Therapeutics, IncS Sale	Director	SSale	−4,000 sh	$54.25	−$217K	13,130
2025-01-02	PTGXProtagonist Therapeutics, IncA Award	Director	AAward	+5,130 sh	—	—	17,130
2025-01-02	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)A Award	Director	AAward	+6,584 sh	—	—	6,584
2024-12-18	ARWRARROWHEAD PHARMACEUTICALS, INC.A Award	Director	AAward	+16.7K sh	$22.99	+$385K	57,111
2024-12-17	ARWRARROWHEAD PHARMACEUTICALS, INC.S Sale	Director	SSale	−3,747 sh	$22.04	−$82.6K	40,378
2024-12-16	ARWRARROWHEAD PHARMACEUTICALS, INC.S Sale	Director	SSale	−3,748 sh	$21.90	−$82.1K	44,125
2024-09-10	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Director	MExercise/Conversion	+8,000 sh	$12.88	+$103K	20,000
2024-09-10	PTGXProtagonist Therapeutics, IncS Sale	Director	SSale	−8,000 sh	$45.00	−$360K	12,000
2024-09-10	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−8,000 sh	—	—	0
2024-07-24	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Director	MExercise/Conversion	+8,000 sh	$12.88	+$103K	20,000
2024-07-24	PTGXProtagonist Therapeutics, IncS Sale	Director	SSale	−8,000 sh	$40.00	−$320K	12,000
2024-07-24	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−8,000 sh	—	—	8,000
2024-06-07	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Director	MExercise/Conversion	+8,000 sh	$12.88	+$103K	20,000
2024-06-07	PTGXProtagonist Therapeutics, IncS Sale	Director	SSale	−8,000 sh	$35.00	−$280K	12,000
2024-06-07	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−8,000 sh	—	—	16,000
2024-06-05	ANNXAnnexon, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+44K sh	—	—	44,000
2024-06-03	Turnstone Biologics Corp.Stock Option (Right to Buy)A Award	Director	AAward	+12.8K sh	—	—	12,770
2024-04-15	Turnstone Biologics Corp.Stock Option (Right to Buy)A Award	Director	AAward	+25.5K sh	—	—	25,540
2024-03-01	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Director	MExercise/Conversion	+13K sh	$6.09	+$79K	24,975
2024-03-01	PTGXProtagonist Therapeutics, IncS Sale	Director	SSale	−13K sh	$31.34	−$407K	12,000
2024-03-01	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−13K sh	—	—	0
2024-01-11	ARWRARROWHEAD PHARMACEUTICALS, INC.S Sale	Director	SSale	−2,634 sh	$37.81	−$99.6K	49,170

Recent filings

Accepted (ET)
Jun 254
Waddill William D.0001104659-26-077761
SEC(opens sec.gov)
Jun 154
Waddill William D.0001553338-26-000001
SEC(opens sec.gov)
Jun 114
Waddill William D.0001104659-26-073049
SEC(opens sec.gov)
Jun 14
Waddill William D.0001104659-26-069047
SEC(opens sec.gov)
Feb 64
Waddill William D.0001104659-26-011575
SEC(opens sec.gov)
Jan 64
Waddill William D.0001104659-26-001478
SEC(opens sec.gov)
Dec 234
Waddill William D.0001553338-25-000005
SEC(opens sec.gov)

Companies

Address

C/O PROTAGONIST THERAPEUTICS, INC. 7707 GATEWAY BLVD., SUITE 140

NEWARK, CA, 94560-1160